Lillian Smith - Apr 1, 2023 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role: VP, Corporate Counsel
Signature: /s/Lillian Smith
Stock symbol: ALLO
Transactions as of: Apr 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 4/5/2023, 06:43 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALLO	Common Stock	Award	$0	+56.5K	+67.44%	$0.00	140K	Apr 1, 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents performance RSUs which shall vest as follows: (1) 33% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 67% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated on March 22nd, 2026 if such threshold has not been met, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after March 22nd, 2028 if such approval has not occurred.

Content

Represents performance RSUs which shall vest as follows: (1) 33% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 67% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated on March 22nd, 2026 if such threshold has not been met, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after March 22nd, 2028 if such approval has not occurred.